{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T12:24:49Z","timestamp":1792499089264,"version":"4.5.0"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["001"],"award-info":[{"award-number":["001"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s12325-025-03218-3","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T03:20:58Z","timestamp":1746674458000},"page":"3045-3058","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Therapeutic Approaches for COVID-19: A Review of Antiviral Treatments, Immunotherapies, and Emerging Interventions"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0625-416X","authenticated-orcid":false,"given":"Maria C. S.","family":"Alves","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0435-1871","authenticated-orcid":false,"given":"Ruana C. C.","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9938-6673","authenticated-orcid":false,"given":"S\u00e9rgio S. P.","family":"de Leit\u00e3o-J\u00fanior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4319-3952","authenticated-orcid":false,"given":"Valdir Q.","family":"de Balbino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,8]]},"reference":[{"issue":"7798","key":"3218_CR1","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","volume":"579","author":"F Wu","year":"2020","unstructured":"Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579(7798):265\u20139. https:\/\/doi.org\/10.1038\/s41586-020-2008-3.","journal-title":"Nature"},{"key":"3218_CR2","doi-asserted-by":"publisher","DOI":"10.52225\/narrax.v1i1.71","author":"A Hamdan","year":"2023","unstructured":"Hamdan A, Eastaugh J, Snygg J, Naidu J, Alhaj I. Coping strategies used by healthcare professionals during COVID-19 pandemic in Dubai: a descriptive cross-sectional study. Narra X. 2023. https:\/\/doi.org\/10.52225\/narrax.v1i1.71.","journal-title":"Narra X"},{"issue":"4","key":"3218_CR3","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1172\/JCI138003","volume":"130","author":"A Casadevall","year":"2020","unstructured":"Casadevall A, Pirofski LA. The convalescent sera option for containing COVID-19. J Clin Investig. 2020;130(4):1545\u20138. https:\/\/doi.org\/10.1172\/JCI138003.","journal-title":"J Clin Investig"},{"key":"3218_CR4","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.biochi.2020.09.018","volume":"179","author":"S Muralidar","year":"2020","unstructured":"Muralidar S, Ambi SV, Sekaran S, Krishnan UM. The emergence of COVID-19 as a global pandemic: understanding the epidemiology, immune response and potential therapeutic targets of SARS-CoV-2. Biochimie. 2020;179:85\u2013100. https:\/\/doi.org\/10.1016\/j.biochi.2020.09.018.","journal-title":"Biochimie"},{"issue":"8","key":"3218_CR5","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa2001017","volume":"382","author":"N Zhu","year":"2020","unstructured":"Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727\u201333. https:\/\/doi.org\/10.1056\/NEJMoa2001017.","journal-title":"N Engl J Med"},{"key":"3218_CR6","unstructured":"Cascella M, Rajnik M, Aleem A, Dulebohn SC, Di Napoli R. Features, evaluation, and treatment of coronavirus (COVID-19). In: StatPearls. StatPearls Publishing; 2024. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK554776\/. Accessed 30 Aug 2024."},{"key":"3218_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113977","volume":"157","author":"AI Abulsoud","year":"2023","unstructured":"Abulsoud AI, El-Husseiny HM, El-Husseiny AA, et al. Mutations in SARS-CoV-2: insights on structure, variants, vaccines, and biomedical interventions. Biomed Pharmacother. 2023;157: 113977. https:\/\/doi.org\/10.1016\/j.biopha.2022.113977.","journal-title":"Biomed Pharmacother"},{"key":"3218_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2020.00870","author":"J D\u00edaz","year":"2020","unstructured":"D\u00edaz J. SARS-CoV-2 molecular network structure. Front Physiol. 2020. https:\/\/doi.org\/10.3389\/fphys.2020.00870.","journal-title":"Front Physiol"},{"issue":"11","key":"3218_CR9","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/s41579-021-00630-8","volume":"19","author":"H Yang","year":"2021","unstructured":"Yang H, Rao Z. Structural biology of SARS-CoV-2 and implications for therapeutic development. Nat Rev Microbiol. 2021;19(11):685\u2013700. https:\/\/doi.org\/10.1038\/s41579-021-00630-8.","journal-title":"Nat Rev Microbiol"},{"issue":"0","key":"3218_CR10","doi-asserted-by":"publisher","first-page":"e04218-23","DOI":"10.1128\/spectrum.04218-23","volume":"0","author":"LC Machado","year":"2024","unstructured":"Machado LC, Dezordi FZ, de Lima GB, et al. Spatiotemporal transmission of SARS-CoV-2 lineages during 2020\u20132021 in Pernambuco\u2014Brazil. Microbiol Spectrum. 2024;0(0):e04218-23. https:\/\/doi.org\/10.1128\/spectrum.04218-23.","journal-title":"Microbiol Spectrum"},{"issue":"1","key":"3218_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s44298-023-00007-z","volume":"1","author":"K Gayvert","year":"2023","unstructured":"Gayvert K, McKay S, Lim WK, et al. Evolutionary trajectory of SARS-CoV-2 genome shifts during widespread vaccination and emergence of Omicron variant. NPJ Viruses. 2023;1(1):1\u201310. https:\/\/doi.org\/10.1038\/s44298-023-00007-z.","journal-title":"NPJ Viruses"},{"issue":"10","key":"3218_CR12","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.3390\/v15102132","volume":"15","author":"S Basak","year":"2023","unstructured":"Basak S, Kayet P, Ghosh M, Chatterjee J, Dutta S. Emergence of genomic diversity in the spike protein of the \u201comicron\u201d variant. Viruses. 2023;15(10):2132. https:\/\/doi.org\/10.3390\/v15102132.","journal-title":"Viruses"},{"issue":"3","key":"3218_CR13","doi-asserted-by":"publisher","first-page":"taaa041","DOI":"10.1093\/jtm\/taaa041","volume":"27","author":"JH Diaz","year":"2020","unstructured":"Diaz JH. Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19. J Travel Med. 2020;27(3):taaa041. https:\/\/doi.org\/10.1093\/jtm\/taaa041.","journal-title":"J Travel Med"},{"issue":"2","key":"3218_CR14","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271-280.e8. https:\/\/doi.org\/10.1016\/j.cell.2020.02.052.","journal-title":"Cell"},{"issue":"6","key":"3218_CR15","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.3390\/biomedicines11061736","volume":"11","author":"M Csobonyeiova","year":"2023","unstructured":"Csobonyeiova M, Smolinska V, Harsanyi S, Ivantysyn M, Klein M. The immunomodulatory role of cell-free approaches in SARS-CoV-2-induced cytokine storm\u2014a powerful therapeutic tool for COVID-19 patients. Biomedicines. 2023;11(6):1736. https:\/\/doi.org\/10.3390\/biomedicines11061736.","journal-title":"Biomedicines"},{"issue":"1","key":"3218_CR16","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.14900","volume":"27","author":"LT Liu","year":"2024","unstructured":"Liu LT, Tsai JJ. Unveiling COVID-19 treatment strategies for immunocompromised individuals: therapeutic innovations and latest findings. Int J Rheum Dis. 2024;27(1): e14900. https:\/\/doi.org\/10.1111\/1756-185X.14900.","journal-title":"Int J Rheum Dis"},{"key":"3218_CR17","doi-asserted-by":"publisher","first-page":"3419","DOI":"10.2147\/JIR.S322831","volume":"14","author":"DM Hertanto","year":"2021","unstructured":"Hertanto DM, Wiratama BS, Sutanto H, Wungu CDK. Immunomodulation as a potent COVID-19 pharmacotherapy: past, present and future. J Inflamm Res. 2021;14:3419\u201328. https:\/\/doi.org\/10.2147\/JIR.S322831.","journal-title":"J Inflamm Res"},{"issue":"2","key":"3218_CR18","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1080\/00325481.2022.2033563","volume":"134","author":"H Al-Hajeri","year":"2022","unstructured":"Al-Hajeri H, Baroun F, Abutiban F, et al. Therapeutic role of immunomodulators during the COVID-19 pandemic\u2014a narrative review. Postgrad Med. 2022;134(2):160\u201379. https:\/\/doi.org\/10.1080\/00325481.2022.2033563.","journal-title":"Postgrad Med"},{"key":"3218_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.glmedi.2023.100041","volume":"2","author":"N Murmu","year":"2024","unstructured":"Murmu N, Sarkar M, Dey S, et al. Efficacy and limitations of repurposed drugs and vaccines for COVID-19. J Med Surg Public Health. 2024;2: 100041. https:\/\/doi.org\/10.1016\/j.glmedi.2023.100041.","journal-title":"J Med Surg Public Health"},{"issue":"8","key":"3218_CR20","doi-asserted-by":"publisher","DOI":"10.2174\/1871526523666230816151614","volume":"23","author":"A Mohiuddin","year":"2023","unstructured":"Mohiuddin A, Mondal S. Advancement of computational design drug delivery system in COVID-19: current updates and future crosstalk\u2014a critical update. Infect Disord Drug Targets. 2023;23(8): e160823219858. https:\/\/doi.org\/10.2174\/1871526523666230816151614.","journal-title":"Infect Disord Drug Targets"},{"key":"3218_CR21","doi-asserted-by":"publisher","unstructured":"de Castro-Nunes P, Ribeiro G da R. Equidade e vulnerabilidade em sa\u00fade no acesso \u00e0s vacinas contra a COVID-19. Rev Panam Salud P\u00fablica. 2022;46:e31. https:\/\/doi.org\/10.26633\/RPSP.2022.31.","DOI":"10.26633\/RPSP.2022.31"},{"key":"3218_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.117765","volume":"254","author":"V Pooladanda","year":"2020","unstructured":"Pooladanda V, Thatikonda S, Godugu C. The current understanding and potential therapeutic options to combat COVID-19. Life Sci. 2020;254: 117765. https:\/\/doi.org\/10.1016\/j.lfs.2020.117765.","journal-title":"Life Sci"},{"key":"3218_CR23","doi-asserted-by":"publisher","unstructured":"Souza JB de, Farias PC de A, Oliveira FHPC de, Albuquerque JPAS de. Abordagens farmacol\u00f3gicas para o tratamento da infec\u00e7\u00e3o ocasionada por SARS-CoV-2: Uma revis\u00e3o integrativa\/Pharmacological approaches for the treatment of infection caused by SARS-CoV-2: an integrative review. Braz J Dev. 2020;6(6):39060\u201339078. https:\/\/doi.org\/10.34117\/bjdv6n6-446.","DOI":"10.34117\/bjdv6n6-446"},{"issue":"3","key":"3218_CR24","doi-asserted-by":"publisher","first-page":"e92","DOI":"10.52225\/narra.v2i3.92","volume":"2","author":"K Sharun","year":"2022","unstructured":"Sharun K, Tiwari R, Yatoo MI, et al. A comprehensive review on pharmacologic agents, immunotherapies and supportive therapeutics for COVID-19. Narra J. 2022;2(3):e92. https:\/\/doi.org\/10.52225\/narra.v2i3.92.","journal-title":"Narra J."},{"issue":"1","key":"3218_CR25","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.3762\/bjoc.20.91","volume":"20","author":"LJ T\u00f3th","year":"2024","unstructured":"T\u00f3th LJ, Krej\u010dov\u00e1 K, Dejmek M, et al. Novel analogues of a nonnucleoside SARS-CoV-2 RdRp inhibitor as potential antivirotics. Beilstein J Org Chem. 2024;20(1):1029\u201336. https:\/\/doi.org\/10.3762\/bjoc.20.91.","journal-title":"Beilstein J Org Chem"},{"key":"3218_CR26","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1016\/B978-0-12-818619-0.00130-1","volume-title":"Molecular medical microbiology","author":"P Hidalgo","year":"2024","unstructured":"Hidalgo P, Gonz\u00e1lez RA. Chapter 103\u2014RNA virus replication. In: Tang YW, Hindiyeh MY, Liu D, Sails A, Spearman P, Zhang JR, editors. Molecular medical microbiology. 3rd ed. New York: Academic Press; 2024. p. 2103\u201314. https:\/\/doi.org\/10.1016\/B978-0-12-818619-0.00130-1.","edition":"3"},{"issue":"45","key":"3218_CR27","doi-asserted-by":"publisher","first-page":"10119","DOI":"10.1021\/acs.jpclett.3c01249","volume":"14","author":"X Wang","year":"2023","unstructured":"Wang X, Xu T, Yao Y, Cheung PPH, Gao X, Zhang L. SARS-CoV-2 RNA-dependent RNA polymerase follows asynchronous translocation pathway for viral transcription and replication. J Phys Chem Lett. 2023;14(45):10119\u201328. https:\/\/doi.org\/10.1021\/acs.jpclett.3c01249.","journal-title":"J Phys Chem Lett"},{"issue":"7","key":"3218_CR28","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/phar.2429","volume":"40","author":"SCJ Jorgensen","year":"2020","unstructured":"Jorgensen SCJ, Kebriaei R, Dresser LD. Remdesivir: review of pharmacology, pre-clinical data, and emerging clinical experience for COVID-19. Pharmacother J Hum Pharmacol Drug Ther. 2020;40(7):659\u201371. https:\/\/doi.org\/10.1002\/phar.2429.","journal-title":"Pharmacother J Hum Pharmacol Drug Ther"},{"issue":"19","key":"3218_CR29","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","volume":"383","author":"JH Beigel","year":"2020","unstructured":"Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19\u2014final report. N Engl J Med. 2020;383(19):1813\u201326. https:\/\/doi.org\/10.1056\/NEJMoa2007764.","journal-title":"N Engl J Med"},{"issue":"11","key":"3218_CR30","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1093\/cid\/ciab536","volume":"73","author":"T Benfield","year":"2021","unstructured":"Benfield T, Bodilsen J, Brieghel C, et al. Improved survival among hospitalized patients with coronavirus disease 2019 (COVID-19) treated with remdesivir and dexamethasone. A nationwide population-based cohort study. Clin Infect Dis. 2021;73(11):2031\u20136. https:\/\/doi.org\/10.1093\/cid\/ciab536.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"3218_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.909","volume":"10","author":"F Pourkarim","year":"2022","unstructured":"Pourkarim F, Pourtaghi-Anvarian S, Rezaee H. Molnupiravir: a new candidate for COVID-19 treatment. Pharmacol Res Perspect. 2022;10(1): e00909. https:\/\/doi.org\/10.1002\/prp2.909.","journal-title":"Pharmacol Res Perspect"},{"issue":"6","key":"3218_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2021.102329","volume":"15","author":"AK Singh","year":"2021","unstructured":"Singh AK, Singh A, Singh R, Misra A. Molnupiravir in COVID-19: a systematic review of literature. Diabetes Metab Syndr Clin Res Rev. 2021;15(6): 102329. https:\/\/doi.org\/10.1016\/j.dsx.2021.102329.","journal-title":"Diabetes Metab Syndr Clin Res Rev"},{"issue":"4","key":"3218_CR33","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s40265-022-01684-5","volume":"82","author":"YY Syed","year":"2022","unstructured":"Syed YY. Molnupiravir: first approval. Drugs. 2022;82(4):455\u201360. https:\/\/doi.org\/10.1007\/s40265-022-01684-5.","journal-title":"Drugs"},{"issue":"6","key":"3218_CR34","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.26239","volume":"14","author":"S Alshanqeeti","year":"2022","unstructured":"Alshanqeeti S, Bhargava A. COVID-19 rebound after paxlovid treatment: a case series and review of literature. Cureus. 2022;14(6): e26239. https:\/\/doi.org\/10.7759\/cureus.26239.","journal-title":"Cureus"},{"issue":"2","key":"3218_CR35","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.28441","volume":"95","author":"B Amani","year":"2023","unstructured":"Amani B, Amani B. Efficacy and safety of nirmatrelvir\/ritonavir (Paxlovid) for COVID-19: a rapid review and meta-analysis. J Med Virol. 2023;95(2): e28441. https:\/\/doi.org\/10.1002\/jmv.28441.","journal-title":"J Med Virol"},{"issue":"1","key":"3218_CR36","doi-asserted-by":"publisher","first-page":"7341493","DOI":"10.1155\/2022\/7341493","volume":"2022","author":"M Marzi","year":"2022","unstructured":"Marzi M, Vakil MK, Bahmanyar M, Zarenezhad E. Paxlovid: mechanism of action, synthesis, and in silico study. BioMed Res Int. 2022;2022(1):7341493. https:\/\/doi.org\/10.1155\/2022\/7341493.","journal-title":"BioMed Res Int"},{"key":"3218_CR37","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.ijid.2020.10.069","volume":"102","author":"S Joshi","year":"2021","unstructured":"Joshi S, Parkar J, Ansari A, et al. Role of favipiravir in the treatment of COVID-19. Int J Infect Dis. 2021;102:501\u20138. https:\/\/doi.org\/10.1016\/j.ijid.2020.10.069.","journal-title":"Int J Infect Dis"},{"issue":"2","key":"3218_CR38","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S2055-6640(20)30016-9","volume":"6","author":"V Pilkington","year":"2020","unstructured":"Pilkington V, Pepperrell T, Hill A. A review of the safety of favipiravir\u2014a potential treatment in the COVID-19 pandemic? J Virus Erad. 2020;6(2):45\u201351. https:\/\/doi.org\/10.1016\/S2055-6640(20)30016-9.","journal-title":"J Virus Erad"},{"issue":"6","key":"3218_CR39","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.1172\/JCI138745","volume":"130","author":"EM Bloch","year":"2020","unstructured":"Bloch EM, Shoham S, Casadevall A, et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Investig. 2020;130(6):2757\u201365. https:\/\/doi.org\/10.1172\/JCI138745.","journal-title":"J Clin Investig"},{"issue":"5","key":"3218_CR40","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1080\/17476348.2023.2208349","volume":"17","author":"A Casadevall","year":"2023","unstructured":"Casadevall A, Joyner MJ, Pirofski LA, et al. Convalescent plasma therapy in COVID-19: unravelling the data using the principles of antibody therapy. Expert Rev Respir Med. 2023;17(5):381\u201395. https:\/\/doi.org\/10.1080\/17476348.2023.2208349.","journal-title":"Expert Rev Respir Med"},{"issue":"3","key":"3218_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.106103","volume":"56","author":"SH Lan","year":"2020","unstructured":"Lan SH, Lai CC, Huang HT, Chang SP, Lu LC, Hsueh PR. Tocilizumab for severe COVID-19: a systematic review and meta-analysis. Int J Antimicrob Agents. 2020;56(3): 106103. https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106103.","journal-title":"Int J Antimicrob Agents"},{"key":"3218_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1293331","author":"J Zhang","year":"2023","unstructured":"Zhang J, Fan X, Zhang X, et al. Efficacy and safety of tocilizumab and baricitinib among patients hospitalized for COVID-19: a systematic review and meta-analysis. Front Pharmacol. 2023. https:\/\/doi.org\/10.3389\/fphar.2023.1293331.","journal-title":"Front Pharmacol"},{"issue":"12","key":"3218_CR43","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.1007\/s42399-020-00610-8","volume":"2","author":"MH Ahmed","year":"2020","unstructured":"Ahmed MH, Hassan A. Dexamethasone for the treatment of coronavirus disease (COVID-19): a review. SN Compr Clin Med. 2020;2(12):2637\u201346. https:\/\/doi.org\/10.1007\/s42399-020-00610-8.","journal-title":"SN Compr Clin Med"},{"issue":"5","key":"3218_CR44","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.dsx.2020.06.054","volume":"14","author":"AK Singh","year":"2020","unstructured":"Singh AK, Majumdar S, Singh R, Misra A. Role of corticosteroid in the management of COVID-19: a systemic review and a Clinician\u2019s perspective. Diabetes Metab Syndr Clin Res Rev. 2020;14(5):971\u20138. https:\/\/doi.org\/10.1016\/j.dsx.2020.06.054.","journal-title":"Diabetes Metab Syndr Clin Res Rev"},{"issue":"17","key":"3218_CR45","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1007\/s40265-021-01620-z","volume":"81","author":"ED Deeks","year":"2021","unstructured":"Deeks ED. Casirivimab\/imdevimab: first approval. Drugs. 2021;81(17):2047\u201355. https:\/\/doi.org\/10.1007\/s40265-021-01620-z.","journal-title":"Drugs"},{"key":"3218_CR46","doi-asserted-by":"publisher","first-page":"102125","DOI":"10.1016\/j.scr.2020.102125","volume":"50","author":"S Xiaojie","year":"2021","unstructured":"Xiaojie S, Yu L, Lei Y, Guang Y, Min Q. Neutralizing antibodies targeting SARS-CoV-2 spike protein. Stem Cell Res. 2021;50:102125. https:\/\/doi.org\/10.1016\/j.scr.2020.102125.","journal-title":"Stem Cell Res"},{"issue":"3","key":"3218_CR47","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.23526","volume":"14","author":"IM Dighriri","year":"2022","unstructured":"Dighriri IM, Alhusayni KM, Mobarki AY, et al. Pfizer-BioNTech COVID-19 vaccine (BNT162b2) side effects: a systematic review. Cureus. 2022;14(3): e23526. https:\/\/doi.org\/10.7759\/cureus.23526.","journal-title":"Cureus"},{"issue":"6","key":"3218_CR48","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.7150\/ijbs.59233","volume":"17","author":"JW Park","year":"2021","unstructured":"Park JW, Lagniton PNP, Liu Y, Xu RH. mRNA vaccines for COVID-19: what, why and how. Int J Biol Sci. 2021;17(6):1446\u201360. https:\/\/doi.org\/10.7150\/ijbs.59233.","journal-title":"Int J Biol Sci"},{"issue":"3","key":"3218_CR49","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.jhep.2021.09.031","volume":"76","author":"GSZ Tun","year":"2022","unstructured":"Tun GSZ, Gleeson D, Al-Joudeh A, Dube A. Immune-mediated hepatitis with the Moderna vaccine, no longer a coincidence but confirmed. J Hepatol. 2022;76(3):747\u20139. https:\/\/doi.org\/10.1016\/j.jhep.2021.09.031.","journal-title":"J Hepatol"},{"issue":"1","key":"3218_CR50","doi-asserted-by":"publisher","first-page":"21464","DOI":"10.1038\/s41598-021-00963-7","volume":"11","author":"F Babamahmoodi","year":"2021","unstructured":"Babamahmoodi F, Saeedi M, Alizadeh-Navaei R, et al. Side effects and immunogenicity following administration of the Sputnik V COVID-19 vaccine in health care workers in Iran. Sci Rep. 2021;11(1):21464. https:\/\/doi.org\/10.1038\/s41598-021-00963-7.","journal-title":"Sci Rep"},{"issue":"4","key":"3218_CR51","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/s41562-021-01079-8","volume":"5","author":"T Hale","year":"2021","unstructured":"Hale T, Angrist N, Goldszmidt R, et al. A global panel database of pandemic policies (Oxford COVID-19 Government Response Tracker). Nat Hum Behav. 2021;5(4):529\u201338. https:\/\/doi.org\/10.1038\/s41562-021-01079-8.","journal-title":"Nat Hum Behav"},{"key":"3218_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2022.102210","volume":"77","author":"N McCann","year":"2022","unstructured":"McCann N, O\u2019Connor D, Lambe T, Pollard AJ. Viral vector vaccines. Curr Opin Immunol. 2022;77: 102210. https:\/\/doi.org\/10.1016\/j.coi.2022.102210.","journal-title":"Curr Opin Immunol"},{"issue":"4","key":"3218_CR53","doi-asserted-by":"publisher","first-page":"393","DOI":"10.3390\/vaccines9040393","volume":"9","author":"M Tobaiqy","year":"2021","unstructured":"Tobaiqy M, Elkout H, MacLure K. Analysis of thrombotic adverse reactions of COVID-19 AstraZeneca Vaccine Reported to EudraVigilance Database. Vaccines. 2021;9(4):393. https:\/\/doi.org\/10.3390\/vaccines9040393.","journal-title":"Vaccines"},{"issue":"4","key":"3218_CR54","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002838","volume":"10","author":"G Levy","year":"2022","unstructured":"Levy G, Guglielmelli P, Langmuir P, Constantinescu SN. JAK inhibitors and COVID-19. J Immunother Cancer. 2022;10(4): e002838. https:\/\/doi.org\/10.1136\/jitc-2021-002838.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"3218_CR55","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12879-020-05730-z","volume":"21","author":"L Walz","year":"2021","unstructured":"Walz L, Cohen AJ, Rebaza AP, et al. JAK-inhibitor and type I interferon ability to produce favorable clinical outcomes in COVID-19 patients: a systematic review and meta-analysis. BMC Infect Dis. 2021;21(1):47. https:\/\/doi.org\/10.1186\/s12879-020-05730-z.","journal-title":"BMC Infect Dis"},{"key":"3218_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103255","volume":"65","author":"M Hoffmann","year":"2021","unstructured":"Hoffmann M, Hofmann-Winkler H, Smith JC, et al. Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity. EBioMedicine. 2021;65: 103255. https:\/\/doi.org\/10.1016\/j.ebiom.2021.103255.","journal-title":"EBioMedicine"},{"issue":"8","key":"3218_CR57","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1038\/s41401-020-00556-6","volume":"42","author":"L Yang","year":"2021","unstructured":"Yang L, Juan PR, Li H, et al. Identification of SARS-CoV-2 entry inhibitors among already approved drugs. Acta Pharmacol Sin. 2021;42(8):1347\u201353. https:\/\/doi.org\/10.1038\/s41401-020-00556-6.","journal-title":"Acta Pharmacol Sin"},{"issue":"9","key":"3218_CR58","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.3390\/v12091058","volume":"12","author":"ZY Low","year":"2020","unstructured":"Low ZY, Farouk IA, Lal SK. Drug repositioning: new approaches and future prospects for life-debilitating diseases and the COVID-19 pandemic outbreak. Viruses. 2020;12(9):1058. https:\/\/doi.org\/10.3390\/v12091058.","journal-title":"Viruses"},{"issue":"6","key":"3218_CR59","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s00228-023-03486-4","volume":"79","author":"ES Vaz","year":"2023","unstructured":"Vaz ES, Vassiliades SV, Giarolla J, Polli MC, Parise-Filho R. Drug repositioning in the COVID-19 pandemic: fundamentals, synthetic routes, and overview of clinical studies. Eur J Clin Pharmacol. 2023;79(6):723\u201351. https:\/\/doi.org\/10.1007\/s00228-023-03486-4.","journal-title":"Eur J Clin Pharmacol"},{"issue":"7","key":"3218_CR60","doi-asserted-by":"publisher","first-page":"2986","DOI":"10.1002\/jmv.27717","volume":"94","author":"VP Chavda","year":"2022","unstructured":"Chavda VP, Patel AB, Vaghasiya DD. SARS-CoV-2 variants and vulnerability at the global level. J Med Virol. 2022;94(7):2986\u20133005. https:\/\/doi.org\/10.1002\/jmv.27717.","journal-title":"J Med Virol"},{"key":"3218_CR61","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.cytogfr.2021.06.001","volume":"63","author":"B Cosar","year":"2022","unstructured":"Cosar B, Karagulleoglu ZY, Unal S, et al. SARS-CoV-2 mutations and their viral variants. Cytokine Growth Factor Rev. 2022;63:10\u201322. https:\/\/doi.org\/10.1016\/j.cytogfr.2021.06.001.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"6","key":"3218_CR62","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1053\/j.gastro.2012.02.012","volume":"142","author":"S Naggie","year":"2012","unstructured":"Naggie S, Sulkowski MS. Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals. Gastroenterology. 2012;142(6):1324-1334.e3. https:\/\/doi.org\/10.1053\/j.gastro.2012.02.012.","journal-title":"Gastroenterology"},{"issue":"10","key":"3218_CR63","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1016\/j.drudis.2021.05.008","volume":"26","author":"ZA Shyr","year":"2021","unstructured":"Shyr ZA, Cheng YS, Lo DC, Zheng W. Drug combination therapy for emerging viral diseases. Drug Discov Today. 2021;26(10):2367\u201376. https:\/\/doi.org\/10.1016\/j.drudis.2021.05.008.","journal-title":"Drug Discov Today"},{"issue":"6","key":"3218_CR64","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1007\/s43440-022-00388-7","volume":"74","author":"L Rahmah","year":"2022","unstructured":"Rahmah L, Abarikwu SO, Arero AG, et al. Oral antiviral treatments for COVID-19: opportunities and challenges. Pharmacol Rep. 2022;74(6):1255\u201378. https:\/\/doi.org\/10.1007\/s43440-022-00388-7.","journal-title":"Pharmacol Rep"},{"issue":"2","key":"3218_CR65","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1001\/jama.2020.10245","volume":"324","author":"M Marovich","year":"2020","unstructured":"Marovich M, Mascola JR, Cohen MS. Monoclonal antibodies for prevention and treatment of COVID-19. JAMA. 2020;324(2):131\u20132. https:\/\/doi.org\/10.1001\/jama.2020.10245.","journal-title":"JAMA"},{"issue":"6","key":"3218_CR66","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/s41577-021-00542-x","volume":"21","author":"PC Taylor","year":"2021","unstructured":"Taylor PC, Adams AC, Hufford MM, de la Torre I, Winthrop K, Gottlieb RL. Neutralizing monoclonal antibodies for treatment of COVID-19. Nat Rev Immunol. 2021;21(6):382\u201393. https:\/\/doi.org\/10.1038\/s41577-021-00542-x.","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"3218_CR67","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.3390\/v13061171","volume":"13","author":"A Chaqroun","year":"2021","unstructured":"Chaqroun A, Hartard C, Schvoerer E. Anti-SARS-CoV-2 vaccines and monoclonal antibodies facing viral variants. Viruses. 2021;13(6):1171. https:\/\/doi.org\/10.3390\/v13061171.","journal-title":"Viruses"},{"issue":"1","key":"3218_CR68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-021-00644-x","volume":"6","author":"W Zhou","year":"2021","unstructured":"Zhou W, Wang W. Fast-spreading SARS-CoV-2 variants: challenges to and new design strategies of COVID-19 vaccines. Signal Transduct Target Ther. 2021;6(1):1\u20136. https:\/\/doi.org\/10.1038\/s41392-021-00644-x.","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"3218_CR69","doi-asserted-by":"publisher","first-page":"216","DOI":"10.14336\/AD.2020.0228","volume":"11","author":"Z Leng","year":"2020","unstructured":"Leng Z, Zhu R, Hou W, et al. Transplantation of ACE2-mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. Aging Dis. 2020;11(2):216\u201328. https:\/\/doi.org\/10.14336\/AD.2020.0228.","journal-title":"Aging Dis"},{"key":"3218_CR70","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.658519","volume":"12","author":"U Anand","year":"2021","unstructured":"Anand U, Jakhmola S, Indari O, et al. Potential therapeutic targets and vaccine development for SARS-CoV-2\/COVID-19 pandemic management: a review on the recent update. Front Immunol. 2021;12: 658519. https:\/\/doi.org\/10.3389\/fimmu.2021.658519.","journal-title":"Front Immunol"},{"issue":"1","key":"3218_CR71","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s12185-020-03029-y","volume":"113","author":"H Asakura","year":"2021","unstructured":"Asakura H, Ogawa H. COVID-19-associated coagulopathy and disseminated intravascular coagulation. Int J Hematol. 2021;113(1):45\u201357. https:\/\/doi.org\/10.1007\/s12185-020-03029-y.","journal-title":"Int J Hematol"},{"issue":"23","key":"3218_CR72","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1182\/blood.2020006000","volume":"135","author":"JM Connors","year":"2020","unstructured":"Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020;135(23):2033\u201340. https:\/\/doi.org\/10.1182\/blood.2020006000.","journal-title":"Blood"},{"key":"3218_CR73","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.thromres.2021.02.010","volume":"201","author":"X Zhou","year":"2021","unstructured":"Zhou X, Cheng Z, Luo L, et al. Incidence and impact of disseminated intravascular coagulation in COVID-19 a systematic review and meta-analysis. Thromb Res. 2021;201:23\u20139. https:\/\/doi.org\/10.1016\/j.thromres.2021.02.010.","journal-title":"Thromb Res"},{"issue":"11","key":"3218_CR74","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1080\/14787210.2021.1915129","volume":"19","author":"SR Savla","year":"2021","unstructured":"Savla SR, Prabhavalkar KS, Bhatt LK. Cytokine storm associated coagulation complications in COVID-19 patients: pathogenesis and management. Expert Rev Anti Infect Ther. 2021;19(11):1397\u2013413. https:\/\/doi.org\/10.1080\/14787210.2021.1915129.","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"23","key":"3218_CR75","doi-asserted-by":"publisher","first-page":"9309","DOI":"10.3390\/ijms21239309","volume":"21","author":"J Maiuolo","year":"2020","unstructured":"Maiuolo J, Mollace R, Gliozzi M, et al. The contribution of endothelial dysfunction in systemic injury subsequent to SARS-Cov-2 infection. Int J Mol Sci. 2020;21(23):9309. https:\/\/doi.org\/10.3390\/ijms21239309.","journal-title":"Int J Mol Sci"},{"key":"3218_CR76","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.876017","volume":"9","author":"HM Al-kuraishy","year":"2022","unstructured":"Al-kuraishy HM, Al-Gareeb AI, Al-Hamash SM, et al. Changes in the blood viscosity in patients with SARS-CoV-2 infection. Front Med. 2022;9: 876017. https:\/\/doi.org\/10.3389\/fmed.2022.876017.","journal-title":"Front Med"},{"issue":"4","key":"3218_CR77","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1007\/s10238-022-00876-3","volume":"23","author":"J Ena","year":"2023","unstructured":"Ena J, Valls V. Therapeutic-dose anticoagulation or thromboprophylaxis with low-molecular-weight heparin for moderate Covid-19: meta-analysis of randomized controlled trials. Clin Exp Med. 2023;23(4):1189\u201396. https:\/\/doi.org\/10.1007\/s10238-022-00876-3.","journal-title":"Clin Exp Med"},{"key":"3218_CR78","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1055\/a-1475-2351","volume":"121","author":"M Goldin","year":"2021","unstructured":"Goldin M, Giannis D, Diab W, et al. Treatment-dose LMWH versus prophylactic\/intermediate dose heparins in high-risk COVID-19 inpatients: rationale and design of the HEP-COVID trial. Thromb Haemost. 2021;121:1684\u201395. https:\/\/doi.org\/10.1055\/a-1475-2351.","journal-title":"Thromb Haemost"},{"issue":"2","key":"3218_CR79","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s00408-023-00599-6","volume":"201","author":"E Pilia","year":"2023","unstructured":"Pilia E, Belletti A, Fresilli S, et al. The effect of heparin full-dose anticoagulation on survival of hospitalized, non-critically ill COVID-19 patients: a meta-analysis of high quality studies. Lung. 2023;201(2):135\u201347. https:\/\/doi.org\/10.1007\/s00408-023-00599-6.","journal-title":"Lung"},{"key":"3218_CR80","doi-asserted-by":"publisher","unstructured":"Egnora LJB, Inso CAV. Effect of therapeutic dose anticoagulation vs prophylactic dose anticoagulation in reducing venous thromboembolism, arterial thrombosis or death events among hospitalized non-critically ill COVID19 pt. Eur Heart J. 2023;44(Supplement_1):ehac779.119. https:\/\/doi.org\/10.1093\/eurheartj\/ehac779.119.","DOI":"10.1093\/eurheartj\/ehac779.119"},{"issue":"3","key":"3218_CR81","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1007\/s11239-022-02681-x","volume":"54","author":"E Pilia","year":"2022","unstructured":"Pilia E, Belletti A, Fresilli S, Finco G, Landoni G. Efficacy and safety of heparin full-dose anticoagulation in hospitalized non-critically ill COVID-19 patients: a meta-analysis of multicenter randomized controlled trials. J Thromb Thrombolysis. 2022;54(3):420\u201330. https:\/\/doi.org\/10.1007\/s11239-022-02681-x.","journal-title":"J Thromb Thrombolysis"},{"issue":"10","key":"3218_CR82","doi-asserted-by":"publisher","first-page":"030006052312013","DOI":"10.1177\/03000605231201340","volume":"51","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Li Q, Sun C, Gu Y, Qi Z, Li J. The effect of nebulized heparin on clinical outcomes in mechanically ventilated patients: a meta-analysis and review of the literature. J Int Med Res. 2023;51(10):03000605231201340. https:\/\/doi.org\/10.1177\/03000605231201340.","journal-title":"J Int Med Res"},{"issue":"3","key":"3218_CR83","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s11239-019-01878-x","volume":"48","author":"M Giustozzi","year":"2019","unstructured":"Giustozzi M, Franco L, Vedovati MC, Becattini C, Agnelli G. Safety of direct oral anticoagulants versus traditional anticoagulants in venous thromboembolism. J Thromb Thrombolysis. 2019;48(3):439\u201353. https:\/\/doi.org\/10.1007\/s11239-019-01878-x.","journal-title":"J Thromb Thrombolysis"},{"issue":"9","key":"3218_CR84","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.3390\/nu14091802","volume":"14","author":"P Kulig","year":"2022","unstructured":"Kulig P, \u0141uczkowska K, Bielikowicz A, Zdrojewska D, Baumert B, Machali\u0144ski B. Vitamin D as a potential player in immunologic control over multiple myeloma cells: implications for adjuvant therapies. Nutrients. 2022;14(9):1802. https:\/\/doi.org\/10.3390\/nu14091802.","journal-title":"Nutrients"},{"issue":"9","key":"3218_CR85","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.3390\/v14091999","volume":"14","author":"D Focosi","year":"2022","unstructured":"Focosi D, Casadevall A. A critical analysis of the use of cilgavimab plus tixagevimab monoclonal antibody cocktail (Evusheld\u2122) for COVID-19 prophylaxis and treatment. Viruses. 2022;14(9):1999. https:\/\/doi.org\/10.3390\/v14091999.","journal-title":"Viruses"},{"issue":"10","key":"3218_CR86","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1038\/s41564-020-00789-5","volume":"5","author":"WS Lee","year":"2020","unstructured":"Lee WS, Wheatley AK, Kent SJ, DeKosky BJ. Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies. Nat Microbiol. 2020;5(10):1185\u201391. https:\/\/doi.org\/10.1038\/s41564-020-00789-5.","journal-title":"Nat Microbiol"},{"key":"3218_CR87","doi-asserted-by":"publisher","unstructured":"Mia MdE, Howlader M, Akter F, Hossain MdM. Preclinical and clinical investigations of potential drugs and vaccines for COVID-19 Therapy: a comprehensive review with recent update. Clin Pathol. 2024;17:2632010X241263054. https:\/\/doi.org\/10.1177\/2632010X241263054.","DOI":"10.1177\/2632010X241263054"},{"key":"3218_CR88","doi-asserted-by":"publisher","unstructured":"V\u2019kovski P, Kratzel A, Steiner S, Stalder H, Thiel V. Coronavirus biology and replication: implications for SARS-CoV-2. Nat Rev Microbiol. 2021;19(3):155\u201370. https:\/\/doi.org\/10.1038\/s41579-020-00468-6.","DOI":"10.1038\/s41579-020-00468-6"},{"issue":"1","key":"3218_CR89","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12954-020-00370-7","volume":"17","author":"A Dunlop","year":"2020","unstructured":"Dunlop A, Lokuge B, Masters D, et al. Challenges in maintaining treatment services for people who use drugs during the COVID-19 pandemic. Harm Reduct J. 2020;17(1):26. https:\/\/doi.org\/10.1186\/s12954-020-00370-7.","journal-title":"Harm Reduct J"},{"issue":"4","key":"3218_CR90","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1038\/s41584-022-00755-x","volume":"18","author":"R Grainger","year":"2022","unstructured":"Grainger R, Kim AHJ, Conway R, Yazdany J, Robinson PC. COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations. Nat Rev Rheumatol. 2022;18(4):191\u2013204. https:\/\/doi.org\/10.1038\/s41584-022-00755-x.","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"3218_CR91","doi-asserted-by":"publisher","first-page":"3228","DOI":"10.3390\/ijms23063228","volume":"23","author":"DA Worku","year":"2022","unstructured":"Worku DA. SARS-CoV-2 associated immune dysregulation and COVID-associated pulmonary Aspergilliosis (CAPA): a cautionary tale. Int J Mol Sci. 2022;23(6):3228. https:\/\/doi.org\/10.3390\/ijms23063228.","journal-title":"Int J Mol Sci"},{"issue":"8","key":"3218_CR92","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.3390\/jpm12081295","volume":"12","author":"R Filip","year":"2022","unstructured":"Filip R, Gheorghita Puscaselu R, Anchidin-Norocel L, Dimian M, Savage WK. Global challenges to public health care systems during the COVID-19 pandemic: a review of pandemic measures and problems. J Pers Med. 2022;12(8):1295. https:\/\/doi.org\/10.3390\/jpm12081295.","journal-title":"J Pers Med"},{"issue":"12","key":"3218_CR93","doi-asserted-by":"publisher","first-page":"3417","DOI":"10.1093\/jac\/dkaa340","volume":"75","author":"D Hodge","year":"2020","unstructured":"Hodge D, Marra F, Marzolini C, et al. Drug interactions: a review of the unseen danger of experimental COVID-19 therapies. J Antimicrob Chemother. 2020;75(12):3417\u201324. https:\/\/doi.org\/10.1093\/jac\/dkaa340.","journal-title":"J Antimicrob Chemother"},{"key":"3218_CR94","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111642","volume":"139","author":"D Kumar","year":"2021","unstructured":"Kumar D, Trivedi N. Disease-drug and drug-drug interaction in COVID-19: Risk and assessment. Biomed Pharmacother. 2021;139: 111642. https:\/\/doi.org\/10.1016\/j.biopha.2021.111642.","journal-title":"Biomed Pharmacother"},{"issue":"4","key":"3218_CR95","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s13337-021-00747-7","volume":"32","author":"D Paul","year":"2021","unstructured":"Paul D, Pyne N, Paul S. Mutation profile of SARS-CoV-2 spike protein and identification of potential multiple epitopes within spike protein for vaccine development against SARS-CoV-2. VirusDisease. 2021;32(4):703\u201326. https:\/\/doi.org\/10.1007\/s13337-021-00747-7.","journal-title":"VirusDisease"},{"issue":"1","key":"3218_CR96","doi-asserted-by":"publisher","first-page":"6873","DOI":"10.1038\/s41598-022-10929-y","volume":"12","author":"A Dutta","year":"2022","unstructured":"Dutta A. Optimizing antiviral therapy for COVID-19 with learned pathogenic model. Sci Rep. 2022;12(1):6873. https:\/\/doi.org\/10.1038\/s41598-022-10929-y.","journal-title":"Sci Rep"},{"issue":"12","key":"3218_CR97","doi-asserted-by":"publisher","first-page":"16180","DOI":"10.1021\/acsnano.0c08494","volume":"14","author":"H Lukas","year":"2020","unstructured":"Lukas H, Xu C, Yu Y, Gao W. Emerging telemedicine tools for remote COVID-19 diagnosis, monitoring, and management. ACS Nano. 2020;14(12):16180\u201393. https:\/\/doi.org\/10.1021\/acsnano.0c08494.","journal-title":"ACS Nano"},{"key":"3218_CR98","doi-asserted-by":"publisher","unstructured":"Gravagnuolo AM, Faqih L, Cronshaw C, Wynn J, Klapper P, Wigglesworth M. High throughput diagnostics and dynamic risk assessment of SARS-CoV-2 variants of concern. eBioMedicine. 2021. https:\/\/doi.org\/10.1016\/j.ebiom.2021.103540.","DOI":"10.1016\/j.ebiom.2021.103540"},{"key":"3218_CR99","doi-asserted-by":"publisher","unstructured":"Kumar S, Nyodu R, Maurya VK, Saxena SK. Morphology, genome organization, replication, and pathogenesis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In: Saxena SK, editor. Coronavirus disease 2019 (COVID-19): epidemiology, pathogenesis, diagnosis, and therapeutics. Berlin: Springer; 2020. pp. 23\u201331. https:\/\/doi.org\/10.1007\/978-981-15-4814-7_3.","DOI":"10.1007\/978-981-15-4814-7_3"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03218-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03218-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03218-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T04:14:18Z","timestamp":1750479258000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03218-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,8]]},"references-count":99,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["3218"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03218-3","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,8]]},"assertion":[{"value":"19 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Maria Cidinaria Silva Alves, Ruana Carolina Cabral da Silva, S\u00e9rgio de S\u00e1 Paiva Leit\u00e3o-J\u00fanior, and Valdir de Queiroz Balbino declare no potential conflicts of interest with respect to the publication of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}